Analyst Ratings For Alder Biopharmaceuticals (NASDAQ:ALDR) (NASDAQ:ALDR)
Today, Mizuho reiterated its Buy rating on Alder Biopharmaceuticals (NASDAQ:ALDR) (NASDAQ:ALDR) with a price target of $29.00.
Some recent analyst ratings include
- 3/28/2018-Mizuho Reiterated Rating of Buy.
- 3/4/2018-Leerink Swann Reiterated Rating of Outperform.
- 9/14/2017-Royal Bank of Canada initiated coverage with a Outperform rating.
Recent Insider Trading Activity For Alder Biopharmaceuticals (NASDAQ:ALDR) (NASDAQ:ALDR)
Alder Biopharmaceuticals (NASDAQ:ALDR) (NASDAQ:ALDR) has insider ownership of 10.60% and institutional ownership of 99.14%.
- On 11/13/2017 Mark James Litton, Insider, sold 16,519 with an average share price of $10.80 per share and the total transaction amounting to $178,405.20.
- On 10/16/2017 Mark James Litton, Insider, sold 16,520 with an average share price of $12.33 per share and the total transaction amounting to $203,691.60.
- On 7/18/2017 Stephen M Dow, Director, bought 25,000 with an average share price of $10.00 per share and the total transaction amounting to $250,000.00.
- On 6/20/2017 Jeffrey T L Smith, VP, sold 585 with an average share price of $20.00 per share and the total transaction amounting to $11,700.00.
- On 1/18/2017 Mark James Litton, Insider, sold 1,498 with an average share price of $23.10 per share and the total transaction amounting to $34,603.80.
- On 1/9/2017 Mark James Litton, Insider, sold 9,516 with an average share price of $23.01 per share and the total transaction amounting to $218,963.16.
- On 12/1/2016 Jeffrey T. L. Smith, VP, sold 3,000 with an average share price of $22.78 per share and the total transaction amounting to $68,340.00.
Recent Trading Activity for Alder Biopharmaceuticals (NASDAQ:ALDR) (NASDAQ:ALDR)
Shares of Alder Biopharmaceuticals (NASDAQ:ALDR) closed the previous trading session at 11.55 up +0.05 0.43% with 11.649999618530273 shares trading hands.